Hassan Salari
Chief Executive Officer at Posh Cosmeceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Weitao Wang | M | 39 | 7 years | |
| Rick Doman | M | - |
EACOM Timber Corp.
 EACOM Timber Corp. Forest ProductsNon-Energy Minerals EACOM Timber Corp. engages in the manufacture and distribution of lumber and wood-based products, and the management of forest resources. It offers stud grade lumber, dimension lumber, machine-stress rated lumber, specialty lumber and engineered woods. The company was founded by Hassan Salari on April 2, 1980 and is headquartered in Montreal, Canada. | 44 years |
| Moira Ong | F | 49 | 14 years | |
| Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 years |
| Daniel Pauly | M | - |
University of British Columbia
| 30 years |
| Angus Livingstone | M | - |
University of British Columbia
| 36 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Bezy | M | 68 | - | |
| Francine Salari | F | 66 | 3 years | |
| Jeremy Curnock-Cook | M | 74 |
EACOM Timber Corp.
EACOM Timber Corp. Forest ProductsNon-Energy Minerals EACOM Timber Corp. engages in the manufacture and distribution of lumber and wood-based products, and the management of forest resources. It offers stud grade lumber, dimension lumber, machine-stress rated lumber, specialty lumber and engineered woods. The company was founded by Hassan Salari on April 2, 1980 and is headquartered in Montreal, Canada. | 16 years |
| Blair Law | M | - | - | |
| Ian M. Mallmann | M | 63 |
University of British Columbia
| 11 years |
| David Filer | M | 76 | 3 years | |
| Audrey Lew | F | 59 |
Chemokine Therapeutics Corp.
 Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 7 years |
| David A. Nordquist | M | - |
University of British Columbia
| 8 years |
| Derek Hemmes | M | - |
University of British Columbia
| 10 years |
| Sebastian Jaimungal | M | - |
University of British Columbia
| 5 years |
| Monica Thornton-Trump | F | - |
University of British Columbia
| 7 years |
| Teck Seng Low | M | 69 |
The University of Southampton
| 8 years |
| Akio Tanaka | M | 54 |
University of British Columbia
| 6 years |
| Richard Azani | M | 65 | 3 years | |
| Li Zhu | F | - |
University of British Columbia
| 3 years |
| R. Culter | M | 48 | - | |
| Brett Kagetsu | M | 54 |
University of British Columbia
| 8 years |
| Nick B. Drake | M | - |
University of British Columbia
| 10 years |
| Timothy Lowinger | M | 60 |
University of British Columbia
| 8 years |
| Terry Hamilton | M | 61 |
University of British Columbia
| 5 years |
| Bin Huang | M | 65 | 4 years | |
| Jonathan Bey | M | 54 |
University of British Columbia
| 5 years |
| Steve Veitch | M | - |
University of British Columbia
| 5 years |
| Trevor Robinson | M | - |
University of British Columbia
| 18 years |
| Wei Jiong Zhang | M | 71 |
University of British Columbia
| 6 years |
| Patric Ouellette | M | - |
University of British Columbia
| 5 years |
| John Priatel | M | 58 |
University of British Columbia
| 11 years |
| Salim Dhanji | M | 44 |
University of British Columbia
| 8 years |
| David Bridge | M | - |
University of British Columbia
| 6 years |
| Dong Xiao Qiu | M | 62 |
University of British Columbia
| 5 years |
| Frank S. Moyle | M | - |
University of British Columbia
| 9 years |
| Kong Lok Yip | M | 48 |
University of British Columbia
| 5 years |
| Chun Ning Shih | M | 60 |
University of British Columbia
| 6 years |
| Wale Bolorunduro | M | - |
University of British Columbia
| 4 years |
| Dominique F. Borrelly | M | 63 | 4 years | |
| Gregory Burnett | M | - |
University of British Columbia
| 6 years |
| Harrison Cookenboo | M | 65 |
University of British Columbia
| 5 years |
| Helge Seetzen | M | - |
University of British Columbia
| 11 years |
| Michelle Robinson | F | 53 |
University of British Columbia
| 6 years |
| Paul Thomas | M | 50 |
University of British Columbia
| 3 years |
| Mark W. Chu | M | 57 |
University of British Columbia
| 8 years |
| Sanjay Bhanot | M | - |
University of British Columbia
| 7 years |
| Mary Garden | F | 65 |
University of British Columbia
| 6 years |
| Lola Maksumova | M | - | - | |
| Andre Marziali | M | - |
University of British Columbia
| 4 years |
| Wendi V. Rodrigueza | M | 58 |
University of British Columbia
| 8 years |
| Douglas Richardson | M | - |
University of British Columbia
| 6 years |
| Kurt Loewen | M | 54 |
University of British Columbia
| 6 years |
| Peeyush Varshney | M | 57 |
University of British Columbia
| 8 years |
| Bashir Jaffer | M | 76 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 2 years |
| Walter Korz | M | 63 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | - |
| Bill Hunter | M | 61 |
University of British Columbia
| 4 years |
| Jacqueline Simpson | F | - |
University of British Columbia
| 11 years |
| Robert E. Cohen | M | - |
University of British Columbia
| 11 years |
| Roger Quick | M | - |
University of British Columbia
| 7 years |
| Darrin Erickson | M | - |
University of British Columbia
| 5 years |
| George Gorzynski | M | - |
University of British Columbia
| 4 years |
| Cyndi Laval | F | - |
University of British Columbia
| 4 years |
| Arie Page | F | 45 |
University of British Columbia
| 8 years |
| Claire Huxtable | F | - |
University of British Columbia
| 6 years |
| Shaun Foy | M | - |
University of British Columbia
| 9 years |
| Brian Leeners | M | 58 |
University of British Columbia
| 7 years |
| Jas Saini | M | 65 |
The University of Southampton
| 7 years |
| Penny White | F | 52 | 1 years | |
| Andrea Zaradic | F | 58 |
University of British Columbia
| 6 years |
| William Edward Mufford | M | - |
University of British Columbia
| 6 years |
| Ying Bin He | M | 62 |
University of British Columbia
| 5 years |
| Kim Oishi | M | 60 |
University of British Columbia
| 7 years |
| Mohammad Azab | M | 68 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 1 years |
| Julien A. François | M | 46 |
University of British Columbia
| 4 years |
| Rob Edel | M | - |
University of British Columbia
| 5 years |
| Peter Smith | M | 55 |
University of British Columbia
| 3 years |
| Peter Hnik | M | - |
University of British Columbia
| 1 years |
| David Birch | M | - |
The University of Southampton
| 4 years |
| Indira Samarasekera | M | 71 |
University of British Columbia
| 9 years |
| John Osth | M | 77 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 4 years |
| Matthias C. Kurth | M | 68 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 6 years |
| David Smalley | M | 63 |
University of British Columbia
| 3 years |
| Marin Katusa | M | 45 |
University of British Columbia
| 4 years |
| C. Piazza | M | 77 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | - |
| Byron Berry | M | - |
University of British Columbia
| 4 years |
| Brad Willock | M | - |
University of British Columbia
| 6 years |
| Sean O'Reilly | M | - |
University of British Columbia
| 4 years |
| Bill M. Gallacher | M | - |
University of British Columbia
| 4 years |
| Martha C. Piper | M | 78 |
University of British Columbia
| 9 years |
| Mike J. Dost | M | - |
University of British Columbia
| 2 years |
| Stephen Kenwood | M | 62 |
University of British Columbia
| 4 years |
| Yen You Zheng | M | 67 |
University of British Columbia
| 9 years |
| Brandon Macdonald | M | - |
University of British Columbia
| 4 years |
| Tim Termuende | M | 61 |
University of British Columbia
| 4 years |
| Guy Ely | M | 71 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | 1 years |
| Mateusz Szeszkowski | M | 52 |
University of British Columbia
| - |
| Donald Evans | M | 59 |
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | - |
| Robert King | M | 57 |
University of British Columbia
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 93 | 93.00% |
| Hong Kong | 4 | 4.00% |
| United Kingdom | 3 | 3.00% |
| Iran | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hassan Salari
- Personal Network
